Skip to main content
. Author manuscript; available in PMC: 2018 Jul 16.
Published in final edited form as: Cancer Res. 2017 Jul 18;77(18):4921–4933. doi: 10.1158/0008-5472.CAN-16-3413

Figure 1. USP9X interacts with Hippo pathway components.

Figure 1

A, USP9X was identified as the top interactor of KIBRA. The chart for the unique peptide counts is presented (left panel). HA-tagged components of the Hippo pathway were transiently expressed in 293 cells and cell lysates were immunoprecipitated with an anti-HA antibody.The co-precipitation of endogenous USP9X with various components was done using USP9X antibody (right panel). B, FPLC analysis of 293 cell lysate.45 fractions (A11-15, B1-15 & C1-11) were collected and proteins combined from two fractions were pooled and run on each lane. Fractions starting from A11 to C11 were shown. Only LATS was found to be strongly co-migrated in the same fractions as USP9X (fractions B5-6). C, D, E, Analytic reciprocal co-immunoprecipitation experiments showing the interaction of USP9X with LATS2, WW45, and KIBRA with LATS2 being the strongest interactor of USP9X. F, Mapping of the LATS2-interacting domain of USP9X. G, Mapping of the USP9X-interacting domain of LATS2.